Cargando…
Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death
BACKGROUND: Dexrazoxane (DEX, ICRF-187) is the only clinically approved cardioprotectant against anthracycline cardiotoxicity. It has been traditionally postulated to undergo hydrolysis to iron-chelating agent ADR-925 and to prevent anthracycline-induced oxidative stress, progressive cardiomyocyte d...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736842/ https://www.ncbi.nlm.nih.gov/pubmed/19623174 http://dx.doi.org/10.1038/sj.bjc.6605192 |
_version_ | 1782171367992459264 |
---|---|
author | Popelová, O Štěrba, M Hašková, P Šimůnek, T Hroch, M Gunčová, I Nachtigal, P Adamcová, M Geršl, V Mazurová, Y |
author_facet | Popelová, O Štěrba, M Hašková, P Šimůnek, T Hroch, M Gunčová, I Nachtigal, P Adamcová, M Geršl, V Mazurová, Y |
author_sort | Popelová, O |
collection | PubMed |
description | BACKGROUND: Dexrazoxane (DEX, ICRF-187) is the only clinically approved cardioprotectant against anthracycline cardiotoxicity. It has been traditionally postulated to undergo hydrolysis to iron-chelating agent ADR-925 and to prevent anthracycline-induced oxidative stress, progressive cardiomyocyte degeneration and subsequent non-programmed cell death. However, the additional capability of DEX to protect cardiomyocytes from apoptosis has remained unsubstantiated under clinically relevant in vivo conditions. METHODS: Chronic anthracycline cardiotoxicity was induced in rabbits by repeated daunorubicin (DAU) administrations (3 mg kg(−1) weekly for 10 weeks). Cardiomyocyte apoptosis was evaluated using TUNEL (terminal deoxynucleotidyl transferase biotin-dUTP nick end labelling) assay and activities of caspases 3/7, 8, 9 and 12. Lipoperoxidation was assayed using HPLC determination of myocardial malondialdehyde and 4-hydroxynonenal immunodetection. RESULTS: Dexrazoxane (60 mg kg(−1)) co-treatment was capable of overcoming DAU-induced mortality, left ventricular dysfunction, profound structural damage of the myocardium and release of cardiac troponin T and I to circulation. Moreover, for the first time, it has been shown that DEX affords significant and nearly complete cardioprotection against anthracycline-induced apoptosis in vivo and effectively suppresses the complex apoptotic signalling triggered by DAU. In individual animals, the severity of apoptotic parameters significantly correlated with cardiac function. However, this effective cardioprotection occurred without a significant decrease in anthracycline-induced lipoperoxidation. CONCLUSION: This study identifies inhibition of apoptosis as an important target for effective cardioprotection against chronic anthracycline cardiotoxicity and suggests that lipoperoxidation-independent mechanisms are involved in the cardioprotective action of DEX. |
format | Text |
id | pubmed-2736842 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-27368422010-09-01 Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death Popelová, O Štěrba, M Hašková, P Šimůnek, T Hroch, M Gunčová, I Nachtigal, P Adamcová, M Geršl, V Mazurová, Y Br J Cancer Translational Therapeutics BACKGROUND: Dexrazoxane (DEX, ICRF-187) is the only clinically approved cardioprotectant against anthracycline cardiotoxicity. It has been traditionally postulated to undergo hydrolysis to iron-chelating agent ADR-925 and to prevent anthracycline-induced oxidative stress, progressive cardiomyocyte degeneration and subsequent non-programmed cell death. However, the additional capability of DEX to protect cardiomyocytes from apoptosis has remained unsubstantiated under clinically relevant in vivo conditions. METHODS: Chronic anthracycline cardiotoxicity was induced in rabbits by repeated daunorubicin (DAU) administrations (3 mg kg(−1) weekly for 10 weeks). Cardiomyocyte apoptosis was evaluated using TUNEL (terminal deoxynucleotidyl transferase biotin-dUTP nick end labelling) assay and activities of caspases 3/7, 8, 9 and 12. Lipoperoxidation was assayed using HPLC determination of myocardial malondialdehyde and 4-hydroxynonenal immunodetection. RESULTS: Dexrazoxane (60 mg kg(−1)) co-treatment was capable of overcoming DAU-induced mortality, left ventricular dysfunction, profound structural damage of the myocardium and release of cardiac troponin T and I to circulation. Moreover, for the first time, it has been shown that DEX affords significant and nearly complete cardioprotection against anthracycline-induced apoptosis in vivo and effectively suppresses the complex apoptotic signalling triggered by DAU. In individual animals, the severity of apoptotic parameters significantly correlated with cardiac function. However, this effective cardioprotection occurred without a significant decrease in anthracycline-induced lipoperoxidation. CONCLUSION: This study identifies inhibition of apoptosis as an important target for effective cardioprotection against chronic anthracycline cardiotoxicity and suggests that lipoperoxidation-independent mechanisms are involved in the cardioprotective action of DEX. Nature Publishing Group 2009-09-01 2009-07-21 /pmc/articles/PMC2736842/ /pubmed/19623174 http://dx.doi.org/10.1038/sj.bjc.6605192 Text en Copyright © 2009 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Translational Therapeutics Popelová, O Štěrba, M Hašková, P Šimůnek, T Hroch, M Gunčová, I Nachtigal, P Adamcová, M Geršl, V Mazurová, Y Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death |
title | Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death |
title_full | Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death |
title_fullStr | Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death |
title_full_unstemmed | Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death |
title_short | Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death |
title_sort | dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death |
topic | Translational Therapeutics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736842/ https://www.ncbi.nlm.nih.gov/pubmed/19623174 http://dx.doi.org/10.1038/sj.bjc.6605192 |
work_keys_str_mv | AT popelovao dexrazoxaneaffordedprotectionagainstchronicanthracyclinecardiotoxicityinvivoeffectiverescueofcardiomyocytesfromapoptoticcelldeath AT sterbam dexrazoxaneaffordedprotectionagainstchronicanthracyclinecardiotoxicityinvivoeffectiverescueofcardiomyocytesfromapoptoticcelldeath AT haskovap dexrazoxaneaffordedprotectionagainstchronicanthracyclinecardiotoxicityinvivoeffectiverescueofcardiomyocytesfromapoptoticcelldeath AT simunekt dexrazoxaneaffordedprotectionagainstchronicanthracyclinecardiotoxicityinvivoeffectiverescueofcardiomyocytesfromapoptoticcelldeath AT hrochm dexrazoxaneaffordedprotectionagainstchronicanthracyclinecardiotoxicityinvivoeffectiverescueofcardiomyocytesfromapoptoticcelldeath AT guncovai dexrazoxaneaffordedprotectionagainstchronicanthracyclinecardiotoxicityinvivoeffectiverescueofcardiomyocytesfromapoptoticcelldeath AT nachtigalp dexrazoxaneaffordedprotectionagainstchronicanthracyclinecardiotoxicityinvivoeffectiverescueofcardiomyocytesfromapoptoticcelldeath AT adamcovam dexrazoxaneaffordedprotectionagainstchronicanthracyclinecardiotoxicityinvivoeffectiverescueofcardiomyocytesfromapoptoticcelldeath AT gerslv dexrazoxaneaffordedprotectionagainstchronicanthracyclinecardiotoxicityinvivoeffectiverescueofcardiomyocytesfromapoptoticcelldeath AT mazurovay dexrazoxaneaffordedprotectionagainstchronicanthracyclinecardiotoxicityinvivoeffectiverescueofcardiomyocytesfromapoptoticcelldeath |